Chemically linked Fab

[1][2] Typically, one of the Fabs binds to a tumour antigen (such as CD30) and the other to a protein on the surface of an immune cell, for example an Fc receptor on a macrophage.

[3] In the late 1990s and early 2000s, clinical trials with chemically linked Fabs were conducted for the treatment of various types of cancer.

Early results were promising,[3][4] but the concept was dropped because of high production costs.

[5] Bi-specific T-cell engagers employ a similar mechanism of action while being cheaper.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.

Example of chemically linked Fabs: two Fab' fragments linked with a thioether, resulting in a F(ab') 2 . The molecule is bound to a tumour cell via the tumour antigen CD30 and to a macrophage via an Fc receptor .